3-179221010-T-C
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4BP7
This summary comes from the ClinGen Evidence Repository: The NM_006218.4(PIK3CA): c.2040T>C (p.Val680=) variant is a synonymous (silent) variant that occurs at a nucleotide that is not conserved according to a PhyloP <0.1 (BP7). The results from in silico splicing predictors MaxEntScan, spliceAI and varSEAK support that this variant does not affect splicing (BP4). In summary, this variant meets the criteria to be classified as Likely benign for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: BP4, BP7; -2 points (VCEP specifications version 1; Approved: 1/31/2021) LINK:https://erepo.genome.network/evrepo/ui/classification/CA2710873/MONDO:0100283/018
Frequency
Consequence
NM_006218.4 synonymous
Scores
Clinical Significance
Conservation
Publications
- overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genesInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- megalencephaly-capillary malformation-polymicrogyria syndromeInheritance: AD Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- vascular malformationInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- Cowden diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Cowden syndrome 5Inheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PIK3CA | ENST00000263967.4 | c.2040T>C | p.Val680Val | synonymous_variant | Exon 14 of 21 | 2 | NM_006218.4 | ENSP00000263967.3 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152180Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000804 AC: 2AN: 248908 AF XY: 0.00000740 show subpopulations
GnomAD4 exome AF: 0.0000240 AC: 35AN: 1460508Hom.: 0 Cov.: 30 AF XY: 0.0000206 AC XY: 15AN XY: 726558 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152180Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74338 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes Benign:1
The NM_006218.4(PIK3CA): c.2040T>C (p.Val680=) variant is a synonymous (silent) variant that occurs at a nucleotide that is not conserved according to a PhyloP <0.1 (BP7). The results from in silico splicing predictors MaxEntScan, spliceAI and varSEAK support that this variant does not affect splicing (BP4). In summary, this variant meets the criteria to be classified as Likely benign for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: BP4, BP7; -2 points (VCEP specifications version 1; Approved: 1/31/2021) -
Inborn genetic diseases Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Cowden syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at